Read quietly unpicks Pfizer’s Indian generics legacy
This article was originally published in Scrip
Executive Summary
Pfizer isn’t saying much, and neither is Aurobindo. But it looks as if the two companies are at least scaling down their 2009 alliance for off-patent medicines, and that they are downgrading the expectations that accompanied the deal. A key factor in the transition is believed to be Pfizer CEO Ian Read, and to his intention to reel back some of the bolder steps towards generic that occurred under his predecessor, Jeff Kindler.